ReviewMicrobiologyOpen2026
Reduction of Hexavalent Chromium by Stenotrophomonas and Bacillus.
Review in MicrobiologyOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Hexavalent chromium [Cr(VI)] is a widespread environmental pollutant, posing a significant health risk to ecosystems and humans. Bioremediation using microorganisms offers a cost-effective strategy for its detoxification. This review highlights recent advances in Cr(VI) reduction by Stenotrophomonas and Bacillus species, two bacterial genera with strong potential for chromium detoxification. Stenotrophomonas species primarily rely on intracellular enzymatic reduction mechanisms, often mediated by chromate reductases such as ChrR and heme proteins that link chromium detoxification with iron homeostasis. In contrast, Bacillus species employ a broader range of strategies, combining intracellular and extracellular enzymatic reduction, biosorption, and bioaccumulation, supported by stress-response and efflux systems that confer exceptional tolerance to Cr(VI). Comparative analysis reveals complementary metabolic strengths: Stenotrophomonas excels in rapid enzymatic detoxification, while Bacillus offers long-term stability through spore formation and surface-associated sequestration. Together, these traits underscore the promise of mixed consortia featuring both genera for scalable and resilient chromium bioremediation systems. Future research integrating omics-guided pathway mapping, microbial engineering, and biosafety control is expected to accelerate the deployment of efficient and safe Cr(VI) bioremediation technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.